Understanding immune responses after CAR-T cell therapy for B cell cancers
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study
This study is looking at how CAR-T cell therapy affects your immune system, especially how well it helps you fight infections, by tracking the immune responses of 130 patients over time to see how different types of CAR-T treatments influence your body's ability to make antibodies and respond to vaccines.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10753555 on NIH RePORTER |
What this research studies
This research investigates how CAR-T cell therapy affects the immune system, particularly focusing on humoral immunity, which is crucial for fighting infections. The study will observe 130 patients who have received CAR-T therapy, analyzing their immune responses over time. By comparing different types of CAR-T therapies, the researchers aim to determine how these treatments impact the body's ability to produce antibodies and respond to vaccines. This research involves collaboration among experts in various fields to ensure a thorough understanding of the therapy's long-term effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have received CAR-T cell therapy for B cell malignancies.
Not a fit: Patients who have not undergone CAR-T cell therapy or those with other types of malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing immune responses in patients undergoing CAR-T therapy, enhancing their overall health and resilience against infections.
How similar studies have performed: Previous research has shown promising results in understanding immune responses following CAR-T therapies, indicating that this approach is building on established findings.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hill, Joshua Aiden — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Joshua Aiden
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.